LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites

Attwa, MW; Kadi, AA; Darwish, HW; Amer, SM; AlRabiah, H

Attwa, MW (reprint author), King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, POB 2457, Riyadh 11451, Saudi Arabia.

CLINICA CHIMICA ACTA, 2018; 485 (): 144

Abstract

Ponatinib (Iclusig (R)) is a multi-targeted tyrosine kinase inhibitor (TKIs). It is active against T315I and other BCR-ABL mutants. Investigation of i......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索